Published in Hepatology on August 01, 2002
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer (2007) 2.09
Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One (2011) 1.98
Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol (2008) 1.58
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology (2012) 1.48
Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini. BMC Genomics (2007) 1.35
FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol (2005) 1.19
Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.14
Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res (2009) 1.12
EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol (2009) 1.08
Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 1.07
Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol (2008) 1.05
Molecular pathogenesis of cholangiocarcinoma. Int J Hepatol (2011) 1.02
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol (2010) 1.01
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. BMC Cancer (2011) 1.00
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. Parasitol Res (2008) 0.96
New insights on cholangiocarcinoma. World J Gastrointest Oncol (2010) 0.94
miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res (2014) 0.93
Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol (2008) 0.93
miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol (2013) 0.90
JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol (2007) 0.90
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch (2007) 0.89
Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma. J Cancer Res Clin Oncol (2006) 0.88
Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) (2011) 0.86
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol (2010) 0.85
Hepatolithiasis and intrahepatic cholangiocarcinoma: A review. World J Gastroenterol (2015) 0.84
Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology (2011) 0.84
Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Dig Liver Dis (2008) 0.82
Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg (2004) 0.82
Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol (2010) 0.82
Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis (2012) 0.82
Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu. Exp Mol Pathol (2010) 0.81
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol (2014) 0.81
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma. Histochem Cell Biol (2011) 0.80
Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. World J Gastroenterol (2011) 0.80
Correlation analysis of liver tumor-associated genes with liver regeneration. World J Gastroenterol (2007) 0.79
Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol (2006) 0.79
Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma. PLoS One (2013) 0.78
HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Arch (2012) 0.78
Genetic and molecular abnormalities in cholangiocarcinogenesis. Anticancer Res (2009) 0.77
Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets. Cancer Gene Ther (2015) 0.77
Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77
Prognostic value of DNA alterations on chromosome 17p13.2 for intrahepatic cholangiocarcinoma. World J Gastroenterol (2007) 0.77
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev (2016) 0.75
Current status of monoclonal antibodies as therapeutic agents for solid cancer. J Gastroenterol (2005) 0.75
The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). J Cancer (2017) 0.75
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Liver fluke induces cholangiocarcinoma. PLoS Med (2007) 3.89
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology (2010) 2.14
Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology (2006) 2.08
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl (2002) 2.07
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology (2014) 1.76
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood (2011) 1.55
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology (2006) 1.40
MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33
Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest (2008) 1.32
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Wnt'er in liver: expression of Wnt and frizzled genes in mouse. Hepatology (2007) 1.27
Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood (2008) 1.27
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology (2005) 1.26
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology (2011) 1.23
Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci (2002) 1.20
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res (2012) 1.19
Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 1.18
Differential gene expression and lipid metabolism in fatty liver induced by acute ethanol treatment in mice. Toxicol Appl Pharmacol (2007) 1.18
Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res (2008) 1.16
Histologic graft assessment after clinical islet transplantation. Transplantation (2009) 1.12
Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. J Occup Health (2008) 1.10
NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol (2010) 1.09
Periostin activates integrin α5β1 through a PI3K/AKT‑dependent pathway in invasion of cholangiocarcinoma. Int J Oncol (2012) 1.09
Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis (2002) 1.09
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl (2003) 1.08
A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology (2010) 1.06
Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol (2005) 1.05
Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol (2010) 1.04
Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. Hepatology (2007) 1.03
Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int J Parasitol (2009) 1.03
Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology (2003) 1.03
Prevalence of swine viral and bacterial pathogens in rodents and stray cats captured around pig farms in Korea. J Vet Med Sci (2013) 1.03
A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res (2010) 1.02
Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer (2010) 1.02
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology (2004) 1.02
Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl (2005) 1.02
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Langerhans cells are not required for graft-versus-host disease. Blood (2010) 1.01
Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation. Lab Invest (2005) 1.00
Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther (2003) 1.00
Preexisting epithelial diversity in normal human livers: a tissue-tethered cytometric analysis in portal/periportal epithelial cells. Hepatology (2013) 0.99
Retracted Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma. Clin Biochem (2012) 0.97
Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J Agric Food Chem (2010) 0.95
Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation. Transplantation (2007) 0.95
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
The role of CT scan in preoperative staging of colorectal carcinoma. J Med Assoc Thai (2005) 0.93
Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radic Biol Med (2013) 0.93
Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World J Gastroenterol (2005) 0.93
Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res (2012) 0.92
Caroli's disease and orthotopic liver transplantation. Liver Transpl (2006) 0.92
Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer (2010) 0.92
ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology (2009) 0.92
Anti-inflammatory, antioxidant and hepatoprotective effects of Thunbergia laurifolia Linn. on experimental opisthorchiasis. Parasitol Res (2012) 0.92
Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. Cancer Biomark (2012) 0.92
Annexin A1: A new immunohistological marker of cholangiocarcinoma. World J Gastroenterol (2013) 0.91
Targeting PDGFR-β in Cholangiocarcinoma. Liver Int (2011) 0.91
A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer (2011) 0.91
Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. Hepatology (2011) 0.91
Memory T cells migrate to and reject vascularized cardiac allografts independent of the chemokine receptor CXCR3. Transplantation (2011) 0.91
Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp Mol Pathol (2010) 0.90
Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol (2012) 0.90
Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer (2010) 0.90
An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology (2005) 0.90
Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis. Cancer Lett (2002) 0.90
Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol (2004) 0.90
Comparative studies on animal models for Opisthorchis viverrini infection: host interaction through susceptibility and pathology. Parasitol Res (2011) 0.90
Gingival overgrowth in dogs associated with clinically relevant cyclosporine blood levels: observations in a canine renal transplantation model. Vet Surg (2008) 0.89
Roles of dendritic cells in murine hepatic warm and liver transplantation-induced cold ischemia/reperfusion injury. Hepatology (2013) 0.89
Webcasting pathology department conferences in a geographically distributed medical center. Hum Pathol (2004) 0.89
Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89
Heterotopic breast epithelial inclusion of the heart: report of a case. Am J Surg Pathol (2010) 0.88
Recipient B cells are not required for graft-versus-host disease induction. Biol Blood Marrow Transplant (2010) 0.88
CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. Cancer Sci (2013) 0.88
Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer (2003) 0.88
Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS One (2012) 0.88
Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol (2006) 0.88
Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett (2005) 0.88